Regencell Bioscience (RGC)
(Real Time Quote from BATS)
$6.75 USD
-0.85 (-11.18%)
Updated Aug 5, 2024 12:26 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Regencell Bioscience Holdings Limited falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 12 | 16 | 0 | 0 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 12 | 16 | 0 | 0 |
Net Property & Equipment | NA | 0 | 1 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 13 | 18 | 0 | 1 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 4 | 3 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 1 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1 | 1 | 4 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 1 | 1 | 4 | 3 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 29 | 29 | 0 | 0 |
Retained Earnings | NA | -17 | -11 | -4 | -3 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | 17 | -4 | -3 |
Total Liabilities & Shareholder's Equity | NA | 13 | 18 | 0 | 1 |
Total Common Equity | 0 | 12 | 17 | -4 | -3 |
Shares Outstanding | 13.00 | 13.00 | 12.60 | 12.60 | NA |
Book Value Per Share | 0.00 | 0.92 | 1.36 | -0.32 | 0.00 |
Fiscal Year End for Regencell Bioscience Holdings Limited falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | 12 |
Receivables | NA | NA | NA | NA | 0 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 0 |
Other Current Assets | NA | NA | NA | NA | 0 |
Total Current Assets | NA | NA | NA | NA | 12 |
Net Property & Equipment | NA | NA | NA | NA | 0 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | NA | NA | 0 |
Deposits & Other Assets | NA | NA | NA | NA | 0 |
Total Assets | NA | NA | NA | NA | 13 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | NA | NA | 0 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 0 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 0 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | NA | NA | 0 |
Total Current Liabilities | NA | NA | NA | NA | 1 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | NA | NA | NA | NA | 0 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | NA | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | NA | NA | 1 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | NA | NA | NA | NA | 0 |
Capital Surplus | NA | NA | NA | NA | 29 |
Retained Earnings | NA | NA | NA | NA | -17 |
Other Equity | NA | NA | NA | NA | 0 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | NA | NA | 12 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 13 |
Total Common Equity | 0 | 0 | 0 | 0 | 12 |
Shares Outstanding | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.92 |